{"id":"ae56f198-e086-53cb-830b-b26d00f0a250","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-crystal-form-sets-solubility","predicate":"is_converted_to","statement":"In an accelerated stability study, form C was converted to the thermodynamically stable and least soluble form A with increased temperature and moisture, the transformation was significantly increased at constant temperature and humidity when trace amounts of form A were already present, four of the seven products tested contained trace amounts of form A, in some tablets transformation was so quick that it reduced shelf life to less than one month, and tablet dissolution of those products was reduced to the extent that it did not comply with USP and FDA specifications.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"2724ef40-3b27-5f50-bab5-6ad4d5e118fd","mechanism_event_label":"The working form of the drug turns into the useless form on the shelf, faster if a trace of the useless form is already there.","subject":{"id":"1f996273-d9f1-5c5c-acd8-ec168cfebd64","slug":"mebendazole-polymorph-c","display_name":"Mebendazole polymorph C","entity_type_key":"chemical_species"},"object":{"id":"c035837e-301e-5643-8242-c1483f7f423d","slug":"mebendazole-polymorph-a","display_name":"Mebendazole polymorph A","entity_type_key":"chemical_species"},"evidence_count":1,"mechanism_event":{"id":"2724ef40-3b27-5f50-bab5-6ad4d5e118fd","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-crystal-form-sets-solubility-event","event_type":"biochemical_relationship","label":"The working form of the drug turns into the useless form on the shelf, faster if a trace of the useless form is already there.","description":"In an accelerated stability study, form C was converted to the thermodynamically stable and least soluble form A with increased temperature and moisture, the transformation was significantly increased at constant temperature and humidity when trace amounts of form A were already present, four of the seven products tested contained trace amounts of form A, in some tablets transformation was so quick that it reduced shelf life to less than one month, and tablet dissolution of those products was reduced to the extent that it did not comply with USP and FDA specifications.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"8a3de69c-7750-57e9-badc-b31ab2c09c80","slug":"storage-heat-and-moisture","display_name":"Storage at raised temperature and relative humidity","entity_type_key":"cellular_process"},"role":"driving_condition","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"55385d39-9458-51e6-9230-a2a4d059d4ab","slug":"solid-state-transformation","display_name":"Solid-state transformation of one crystal form into another","entity_type_key":"cellular_process"},"role":"process","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"d21e579a-6e2c-5edc-8c44-b1a1f0269e5a","slug":"tablet-dissolution","display_name":"Tablet dissolution against USP and FDA specifications","entity_type_key":"cellular_process"},"role":"failed_specification","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"bd95c09d-7613-5fed-b54a-b918e25f6551","slug":"aqueous-solubility","display_name":"Aqueous solubility and dissolution rate of the solid drug","entity_type_key":"cellular_process"},"role":"lost_property","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"1f996273-d9f1-5c5c-acd8-ec168cfebd64","slug":"mebendazole-polymorph-c","display_name":"Mebendazole polymorph C","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"c035837e-301e-5643-8242-c1483f7f423d","slug":"mebendazole-polymorph-a","display_name":"Mebendazole polymorph A","entity_type_key":"chemical_species"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/mebendazole-research/19691117.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"6005cbf9afb4151467910164f873d0956382c3bcc10cac8514326385b32e32b1\", \"start_char\": 0, \"end_char\": 1296, \"text_sha256\": \"6005cbf9afb4151467910164f873d0956382c3bcc10cac8514326385b32e32b1\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Accelerated stability study of mebendazole tablets under ICH storage conditions","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Storage at 30 degrees with 65% relative humidity and at 40 degrees with 75% relative humidity","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Solid-state kinetics on marketed products, modelled with the Johnson-Mehl-Avrami-Erofeyev-Kolmogorov equation. It measures dissolution rather than patient outcome.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.","comparator":null,"unit":null,"notes":"","entity":{"slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Pharmaceutical product","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The working form of the drug turns into the useless form on the shelf, faster if a trace of the useless form is already there.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[mbz-p19691117] Characterization of polymorph transformations that decrease the stability of tablets containing the WHO essential drug mebendazole. (2010). https://pubmed.ncbi.nlm.nih.gov/19691117/ DOI: 10.1002/jps.21899","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Tablets","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"cdff02b9-1c62-5ddb-b148-5cd98ea7f40e","evidence_kind":"source_excerpt","locator":"Lines 381-392","start_line":381,"end_line":392,"excerpt":"### mbz-crystal-form-sets-solubility\nIn an accelerated stability study, form C was converted to the thermodynamically stable and least soluble form A with increased temperature and moisture, the transformation was significantly increased at constant temperature and humidity when trace amounts of form A were already present, four of the seven products tested contained trace amounts of form A, in some tablets transformation was so quick that it reduced shelf life to less than one month, and tablet dissolution of those products was reduced to the extent that it did not comply with USP and FDA specifications.\nCondition category: normal\nnutrient_topic: Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.\nplain_language: The working form of the drug turns into the useless form on the shelf, faster if a trace of the useless form is already there.\norganism: Pharmaceutical product\ntissue_or_cell_type: Tablets\nexperimental_model: Accelerated stability study of mebendazole tablets under ICH storage conditions\nlimitations: Solid-state kinetics on marketed products, modelled with the Johnson-Mehl-Avrami-Erofeyev-Kolmogorov equation. It measures dissolution rather than patient outcome.\nexposure: Storage at 30 degrees with 65% relative humidity and at 40 degrees with 75% relative humidity\nevidence_span: {\"source_cache\": \"artifacts/mebendazole-research/19691117.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"6005cbf9afb4151467910164f873d0956382c3bcc10cac8514326385b32e32b1\", \"start_char\": 0, \"end_char\": 1296, \"text_sha256\": \"6005cbf9afb4151467910164f873d0956382c3bcc10cac8514326385b32e32b1\"}\n[mbz-p19691117] Characterization of polymorph transformations that decrease the stability of tablets containing the WHO essential drug mebendazole. (2010). https://pubmed.ncbi.nlm.nih.gov/19691117/ DOI: 10.1002/jps.21899","model_system":"Accelerated stability study of mebendazole tablets under ICH storage conditions","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [mbz-p19691117] Characterization of polymorph transformations that decrease the stability of tablets containing the WHO essential drug mebendazole. (2010). https://pubmed.ncbi.nlm.nih.gov/19691117/ DOI: 10.1002/jps.21899","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"06104773-03d0-5e5c-b9da-eb484e7be657","stable_key":"import-f2ec2007-88ff-5a96-a73b-8b5085e9cea9","title":"Mebendazole: the tubulin it binds, why that is selective, the crystal form that decides whether any of it works, and the off-target that became an oncology programme (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"58b652636677e5033fd1dd555744485fcef18f21a97dcf68723fe072b656f413","revision_id":"a2cd9c22-0549-52ca-a653-8a0c2362ec85","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}